Dr. Settleman is the Senior Vice President and Chief Scientific Officer for Oncology Research and Development at Pfizer. Dr. Settleman leads all oncology research from the beginning stages of discovery to proof of concept clinical studies. He is an internationally recognized leader in molecularly targeted cancer therapeutics, personalized cancer medicine, and mechanisms of cancer drug resistance. Prior to joining Pfizer, Jeff held numerous notable positions in both academic research and drug discovery. Most recently, Jeff had served as Distinguished Principal Investigator and Head of Oncology Research at Calico Life Sciences. Prior to joining Calico, Jeff led Discovery Oncology at Genentech. Before shifting to industry, Jeff served as a Professor at the Harvard School of Medicine for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology. During that same timeframe, he also served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center. Jeff received his B.A. degree in Neuroscience from the University of Pennsylvania and a Ph.D. in Genetics from Yale University. He pursued post-doctoral training at the Whitehead Institute for Biomedical Research at MIT. Jeff has authored more than 240 peer-reviewed publications, many of which have appeared in Cell, Science, and Nature.